Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119805924 | 11980592 | 4 | F | 201505 | 20160718 | 20160129 | 20160729 | PER | US-PFIZER INC-2016045490 | PFIZER | 63.00 | YR | F | Y | 102.40000 | KG | 20160729 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119805924 | 11980592 | 1 | PS | SUTENT | SUNITINIB MALATE | 1 | 50 MG, DAILY (4 WEEKS ON / 2 WEEKS OFF) | Y | 21938 | 50 | MG | CAPSULE, HARD | |||||||
| 119805924 | 11980592 | 2 | SS | SUTENT | SUNITINIB MALATE | 1 | 50 MG, DAILY (3 WEEKS ON / 2 WEEKS OFF) | Y | 21938 | 50 | MG | CAPSULE, HARD | |||||||
| 119805924 | 11980592 | 3 | SS | SUTENT | SUNITINIB MALATE | 1 | 50 MG, DAILY (2 WEEKS ON / 1 WEEKS OFF) | Y | 21938 | 50 | MG | CAPSULE, HARD | |||||||
| 119805924 | 11980592 | 4 | SS | SUTENT | SUNITINIB MALATE | 1 | 50 MG, DAILY (1 WEEK ON / 1 WEEK OFF) | Y | 21938 | 50 | MG | CAPSULE, HARD | |||||||
| 119805924 | 11980592 | 5 | SS | SUTENT | SUNITINIB MALATE | 1 | UNK (37.5 1WEEK ON + 1 WEEK OFF ) | Y | 21938 | CAPSULE, HARD | |||||||||
| 119805924 | 11980592 | 6 | SS | SUTENT | SUNITINIB MALATE | 1 | UNK (37.5) | Y | 21938 | CAPSULE, HARD | |||||||||
| 119805924 | 11980592 | 7 | C | KLONOPIN | CLONAZEPAM | 1 | UNK (0.1) | 0 | TRANSDERMAL PATCH | ||||||||||
| 119805924 | 11980592 | 8 | C | KLONOPIN | CLONAZEPAM | 1 | UNK | 0 | TRANSDERMAL PATCH | ||||||||||
| 119805924 | 11980592 | 9 | C | COZAAR | LOSARTAN POTASSIUM | 1 | UNK | 0 | |||||||||||
| 119805924 | 11980592 | 10 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | UNK | 0 | |||||||||||
| 119805924 | 11980592 | 11 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 119805924 | 11980592 | 1 | Metastatic renal cell carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 119805924 | 11980592 | OT |
| 119805924 | 11980592 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 119805924 | 11980592 | Alopecia | |
| 119805924 | 11980592 | Blister | |
| 119805924 | 11980592 | Ear infection | |
| 119805924 | 11980592 | Feeling cold | |
| 119805924 | 11980592 | Headache | |
| 119805924 | 11980592 | Hypertension | |
| 119805924 | 11980592 | Hypothyroidism | |
| 119805924 | 11980592 | Nausea | |
| 119805924 | 11980592 | Stomatitis | |
| 119805924 | 11980592 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 119805924 | 11980592 | 4 | 20150501 | 0 | ||
| 119805924 | 11980592 | 5 | 201601 | 0 | ||
| 119805924 | 11980592 | 6 | 201605 | 0 | ||
| 119805924 | 11980592 | 8 | 20160201 | 0 | ||
| 119805924 | 11980592 | 9 | 201505 | 0 | ||
| 119805924 | 11980592 | 10 | 201505 | 0 |